Hikma Pharmaceuticals Plc (HKMPF) Receives Average Rating of “Hold” from Analysts
Hikma Pharmaceuticals Plc (OTC:HKMPF) has been given an average rating of “Hold” by the seven research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company.
A number of equities research analysts recently issued reports on HKMPF shares. ValuEngine upgraded shares of Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a report on Thursday, July 27th. Morgan Stanley reissued an “equal weight” rating on shares of Hikma Pharmaceuticals Plc in a research report on Tuesday, August 8th. Numis Securities Ltd reissued an “add” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Jefferies Group LLC raised shares of Hikma Pharmaceuticals Plc from an “underperform” rating to a “hold” rating in a research report on Monday, August 21st. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Hikma Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 22nd.
Hikma Pharmaceuticals Plc (OTC:HKMPF) opened at 15.65 on Friday. The firm has a 50-day moving average price of $16.64 and a 200 day moving average price of $21.87. Hikma Pharmaceuticals Plc has a 52-week low of $15.10 and a 52-week high of $28.80. The stock has a market capitalization of $3.76 billion and a price-to-earnings ratio of 22.68.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.